COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

News and Announcements

All | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

Displaying 1 - 20 of 261
Proteogenomic Characterization of Small Cell Lung Cancer: A Pathway to Personalized Medicine

Small cell lung cancer (SCLC) is an aggressive form of lung malignancy with historically poor prognoses and limited options for targeted treatment. The low availability of suitable biospecimens has also hampered large molecular characterization efforts.


Deciphering the Tumor Microenvironment: A Proteogenomic Pan-Cancer Analysis

The tumor microenvironment (TME) is a complex network which plays a crucial role in cancer progression and treatment responses. In a recently published Pan Cancer analysis, the Clinical Proteomic Tumor Analysis...


Advancing Personalized Treatment Strategies for Patients with Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) is a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid cells in the bone marrow and blood. AML is known for its heterogeneity, presenting challenges in treatment and predicting patient outcomes.


Excellence in Proteomics Research: A Conversation with Jeffrey Whiteaker

The following is the second entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of proteomics research with Jeffrey Whitaker, PhD, Director of Proteomics within the Paulovich Lab at...


CPTAC Collaboration with Morehouse School Of Medicine Promotes Diversity Of Samples For Proteogenomic Analysis

A new collaboration between the Morehouse School of Medicine (MSM) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) aims to enhance diversity of cancer patients included in proteogenomic studies.


Integrating Molecular and Computational Techniques in Biology with Natalie Clark

The following is the first entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss molecular and computational techniques in biology with Natalie Clark, PhD from the Proteomics Platform at the Broad...


Sweden’s Lund University and United States National Cancer Institute Sign Extension of MOU for Proteogenomics Cancer Research

The National Cancer Institute (NCI) and Lund University in Sweden are pleased to announce the signing of an extension to their memorandum of understanding (MOU) for proteogenomics cancer research. The MOU, involving NCI’s International Cancer Proteogenome Consortium (ICPC) and Clinical Proteomic...


Improving Cholangiocarcinoma Subtype Classification Unveils Therapeutic Opportunities

Intrahepatic cholangiocarcinomas (iCC) pose a diagnostic and treatment challenge due to their rarity and inter/intrapatient heterogeny.


Revolutionizing Liver Cancer Treatments: The Power of Organoid Models

Proteogenomic characterization of patient tissues has enriched our understanding of liver cancer, uncovering potential therapeutic targets, new subtypes, and offering hope for more effective treatments. However, there remains a gap in translating these findings into clinical practice.


The Cancer Imaging Archive Releases AI-Ready CPTAC Imaging Annotations to Facilitate Imaging-Omics Cancer Research

The Cancer Imaging Archive (TCIA), managed by the National Cancer Institute's Cancer Imaging Program (CIP), collects, curates, and hosts digital histopathology and standard-of-care radiology imaging from CPTAC-enrolled patients to provide data for imaging-omics research.    Algorithmic analysis of...


Illuminating Endometrial Carcinoma through Proteogenomics and Deep Learning

Recent strides in the field of genomics, exemplified by initiatives like The Cancer Genome Atlas (TCGA), have illuminated the genetic landscape of endometrial carcinoma (EC). The identification of four distinct EC...


Introducing a Suite of Pan-Cancer Multi-omic Papers from CPTAC

Researchers from the National Cancer Institute’s (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) have produced a resource of global proteomic and post-translational modifications, whole genome and whole exome sequencing, miRNA and totalRNA sequencing, DNA methylation, imaging, and clinical...


Novel 64-Protein Signature Predicts Treatment Response in High-Grade Serous Ovarian Cancer

In an effort recently published in Cell, CPTAC researchers aimed to identify patients with high-grade serous ovarian cancer (HGSOC) who may not respond to standard therapies. At present, there is no way...


PepQuery2: Empowering Proteomics Researchers with Ultrafast Data Analysis

Recently published in Nature Communications, PepQuery2 is a powerful tool that facilitates fast and targeted identification of both new and existing peptides in proteomics datasets obtained from mass spectrometry experiments. It...


ETH Zürich (Switzerland) and United States National Cancer Institute Sign Extension of MOU for Proteogenomics Cancer Research

The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Switzerland International Cancer Proteogenome Consortium (ICPC) team at ETH Zürich are pleased to announce the formalization of an extension to their memorandum of understanding (MOU) for collaborative...


The MONTE Workflow: Enabling Deep Analysis of Sample-Limited Tissues

The limited availability of patient tissue samples poses a constant challenge for omics researchers, particularly in determining which analyses are feasible based on sample input requirements. Existing parallel workflows for multi-omic analyses have yielded valuable insights but are often restricted...


NCI Welcomes Renewed Commitments to the Cancer Moonshot with Taiwan

The United States National Cancer Institute (NCI) and Taiwan are pleased to announce the signing of an extension to their memoranda of understanding (MOUs) for proteogenomics cancer research with Academia Sinica and Chang Gung University. This extension marks a renewed commitment to the collaboration...


Integrated Glycoproteomic Characterization Reveals Molecular Features of ccRCC

Glycosylation is a ubiquitous type of protein modification that is associated with biological functions and diseases, including cancer. Often found on cell surface or secreted into circulation, glycoproteins can be leveraged for diagnosis and treatment.


Uncovering Cellular Architecture and Molecular Characteristics in Clear Cell Renal Cell Carcinoma

Clear cell renal cell carcinoma (ccRCC) is a common type of kidney cancer that originates from the cells of the renal tubules. Recent research has focused on identifying tumor-cell-specific markers to provide mechanistic insights into cancer etiology and support the development of novel targeted...


CPTAC Investigators Assess Coring and Laser Microdissection Techniques for Proteogenomic Analyses

Despite unprecedented advances in the development of targeted- and immuno-therapies for various cancer types, pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer-related death worldwide. A comprehensive characterization of PDAC is critical for the development of new therapies...


Pages